Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17484752 | 0.76 | ALDH1A1 (0.41) | APEX1ALDH1A1NLRP3GAAMAPT | |
| SCHEMBL6365691 | 0.75 | MAPT (0.38) | APEX1ALDH1A1NLRP3TDP1MAPT | |
| SCHEMBL6365346 | 0.73 | ALDH1A1 (0.52) | APEX1ALDH1A1NLRP3GAAMAPT | |
| SCHEMBL16076280 | 0.68 | TDP1 (0.47) | ALDH1A1TDP1GAAMAPT | |
| SCHEMBL19268642 | 0.68 | TDP1 (0.47) | ALDH1A1TDP1GAAMAPT | |
| SCHEMBL8390812 | 0.66 | SIGMAR1 (0.46) | ALDH1A1TDP1 | |
| SCHEMBL3732801 | 0.66 | SMN1; SMN2 (0.43) | APEX1ALDH1A1NLRP3TDP1GAA | |
| SCHEMBL12233164 | 0.65 | — | — | |
| SCHEMBL8809555 | 0.65 | GAA (0.48) | ALDH1A1TDP1GAAMAPTL3MBTL1 | |
| SCHEMBL9921596 | 0.64 | GAA (0.38) | APEX1ALDH1A1NLRP3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | Northrop Grumman Innovation Systems, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-20160199346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2016-07-14 | — | — | US | disclosed |
| US-9226915-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | EPICENTRX, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150246020-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2015-09-03 | — | — | US | disclosed |
| US-8927527-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | EPICENTRX, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130123216-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | ALLIANT TECHSYSTEMS INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8299053-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | RADIORX, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8178698-B2 | Methods of synthesizing cyclic nitro compounds | ALLIANT TECHSYSTEMS INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110130572-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | ALLIANT TECHSYSTEMS INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7745643-B2 | chemical synthesizing a N-(haloacetyl)-3,3-dinitro-azetidine compound; anticarciogenic, antiinflammatory, antihypoxic, antidiabetic agent; cardiovascular and autoimmune disease; rheumatoid arthritis, diabetic retinopathy | ALLIANT TECHSYSTEMS INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090163466-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | RADIORX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090093644-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | ALLIANT TECHSYSTEMS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7507842-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | RADIORX, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070135384-A1 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | RADIORX, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123216-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | APEX1 144/4885ALDH1A1 1432/4885NLRP3 559/4885 |
| US-20160199346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | APEX1 144/4885ALDH1A1 1432/4885NLRP3 559/4885 |
| US-20110130572-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | NOS2, NOS1, NOS3 | APEX1 53/4885ALDH1A1 1408/4885NLRP3 965/4885 |
| US-20150246020-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | APEX1 144/4885ALDH1A1 1432/4885NLRP3 559/4885 |
| US-20090093644-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | NOS2, NOS1, NOS3 | APEX1 53/4885ALDH1A1 1408/4885NLRP3 965/4885 |
| US-20180085346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | APEX1 144/4885ALDH1A1 1432/4885NLRP3 559/4885 |
| US-20070135384-A1 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | NOS1, NOS2, NOS3 | APEX1 144/4885ALDH1A1 1432/4885NLRP3 559/4885 |
| US-20090163466-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | APEX1 144/4885ALDH1A1 1432/4885NLRP3 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.